Alkermes plc (8AK.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:05AM CEST
| Previous Close | 22.00 |
| Open | 23.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's Range | 23.00 - 23.00 |
| 52 Week Range | 20.15 - 29.80 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 3.793B |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | 7.69 |
| EPS (TTM) | 2.86 |
| Earnings Date | Jul 22, 2024 - Jul 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.50 |
Investor's Business DailyThe Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
ZacksAlkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
PR NewswireAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.
© 2024 Yahoo. All rights reserved.